A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma

PURPOSE: The safety and clinical efficacy of WT1 human leukocyte antigen (HLA) class I peptide vaccine have been established, but the safety of a cocktail vaccine of WT1 HLA class I and II peptides has not. To verify its safety, we performed a phase I clinical trial for patients with recurrent malig...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuboi, Akihiro, Hashimoto, Naoya, Fujiki, Fumihiro, Morimoto, Soyoko, Kagawa, Naoki, Nakajima, Hiroko, Hosen, Naoki, Nishida, Sumiyuki, Nakata, Jun, Morita, Satoshi, Sakamoto, Junichi, Oji, Yusuke, Oka, Yoshihiro, Sugiyama, Haruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394509/
https://www.ncbi.nlm.nih.gov/pubmed/30430205
http://dx.doi.org/10.1007/s00262-018-2274-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394509/
https://www.ncbi.nlm.nih.gov/pubmed/30430205
http://dx.doi.org/10.1007/s00262-018-2274-1

Ejemplares similares